Genitourinary Cancers

The bkActiv S series is designed to guide nonsurgical urologic, colorectal, and pelvic floor procedures.

The Cancer BioShield platform is being assessed as a treatment for lymphopenia in adult patients with refractory or relapsed solid tumors, including genitourinary tumors.

ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.

"We’ve achieved a lot, but the focus now must shift from cure alone to comprehensive, patient-centered care," says Vladimir Hugec, MD.

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.

The approval is supported by data from the phase 3 CheckMate-67T trial.

The study showed significant reductions in both anxiety and depressive symptoms following the intervention.

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.

“As health care professionals, we should take a multidisciplinary approach to addressing the stress of a cancer diagnosis by helping mitigate financial toxicity, treatment burden, and emotional impact on both the patient and their family," says Mouneeb M. Choudry, MD.

"I think the micronized formulation is something to think about," says Gautam Jayram, MD.

The cisplatin drug shortage was first announced on February 10, 2023.

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by December 29, 2024.

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.

“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option," says Timothy J. Daskivich, MD.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

The positioning system would allow patients with cancer to undergo radiation therapy in an upright, seated position.

About 1 of every 5 patients with stage I seminoma relapses; however, “the level of evidence supporting the use of currently defined risk factors in decision making is low,” wrote lead author Thomas Wagner, MD, and coinvestigators.

“Our findings show that AI chatbots provided accurate information with little misinformation. However, the information was provided at a college reading level and with little actionability," says Abdo E. Kabarriti, MD, FACS.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

Dr. Avi Baskin and Dr. Katsuto Shinohara were honored for their extraordinary work.

"We are confident that surgery for [testicular seminoma] will be included into treatment guidelines in the near future,” says Sia Daneshmand, MD.